Therapy in Amyotrophic Lateral Sclerosis (ALS): an unexpected evolving scenario

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options.
• Riluzole and edaravone are approved treatments, but more effective disease-modifying therapies are urgently needed.

Purpose of the Study:

• To review the current state of drug development for ALS.
• To highlight the potential of precision medicine and genetic discoveries in advancing ALS therapeutics.
• To identify challenges and opportunities in translating research into effective treatments.

Main Methods:

• Literature review of current ALS treatments and research.
• Analysis of recent genetic discoveries and their implications for drug development.
• Discussion of challenges in clinical translation and diagnosis.

Main Results:

• Current treatments offer modest benefits; significant unmet need exists for disease-modifying drugs.
• Genetic research reveals diverse disease mechanisms, supporting precision medicine approaches.
• Translating basic science and animal model findings to human trials remains a major hurdle.

Conclusions:

• Targeting divergent disease mechanisms through precision medicine is a promising strategy for ALS.
• Overcoming challenges in research translation and diagnosis is crucial for developing effective ALS therapies.
• ALS research may accelerate drug development for other neurodegenerative diseases.